Impact of Nucleic Acid Amplification Test on Clinical Outcomes in Patients with Infection

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 Mar 29

PMID 36978295

Authors

Yota Yamada

Motoyasu Miyazaki

Hisako Kushima

Yukie Komiya

Akio Nakashima

Hiroshi Ishii

Osamu Imakyure

Affiliations

Soon will be listed here.

Abstract

A nucleic acid amplification test (NAAT) is recommended to determine whether or not patients have a infection (CDI) when the glutamate dehydrogenase activity assay is positive and the rapid membrane enzyme immunoassays for toxins is negative. In our hospital, a NAAT was introduced to diagnose CDI precisely in April 2020. This study aimed to investigate the impact of a NAAT on the clinical outcomes in patients with CDI at our hospital. Seventy-one patients diagnosed with CDI between April 2017 and March 2022 were included in our study. Patients with CDI were divided into two groups: before (pre-NAAT) and after (post-NAAT) the introduction of NAAT. The clinical outcome was compared between the two groups. Of the 71 patients with CDI, 41 were sorted into the pre-NAAT group and 30 into the post-NAAT group. The clinical cure rate was significantly higher in the post-NAAT group compared to the pre-NAAT group (76.7% vs. 48.8%, = 0.018). In the multivariable analysis, the clinical cure was significantly associated with the introduction of NAAT ( = 0.022). Our findings suggest that the introduction of NAAT can improve the clinical outcomes in CDI patients.

Citing Articles

Emerging Diagnostics in Infection.

Hulme J Int J Mol Sci. 2024; 25(16).

PMID: 39201359 PMC: 11354687. DOI: 10.3390/ijms25168672.

References

Windsor J, Kaplan G . Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019; 21(8):40. DOI: 10.1007/s11894-019-0705-6. View

Guinta M, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E . Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. Ann Clin Microbiol Antimicrob. 2017; 16(1):77. PMC: 5713042. DOI: 10.1186/s12941-017-0252-7. View

Goldenberg S . Public reporting of Clostridium difficile and improvements in diagnostic tests. Infect Control Hosp Epidemiol. 2011; 32(12):1231-2. DOI: 10.1086/663014. View

Beaulieu C, Dionne L, Julien A, Longtin Y . Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm. Clin Microbiol Infect. 2014; 20(10):1067-73. DOI: 10.1111/1469-0691.12676. View

Fong K, Fatica C, Hall G, Procop G, Schindler S, Gordon S . Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level?. Infect Control Hosp Epidemiol. 2011; 32(9):932-3. DOI: 10.1086/661789. View

Barker A, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R . A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017; 72(11):3177-3180. PMC: 5890711. DOI: 10.1093/jac/dkx254. View

Badger V, Ledeboer N, Graham M, Edmiston Jr C . Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr. 2012; 36(6):645-62. DOI: 10.1177/0148607112446703. View

Yoldas O, Altindis M, Cufali D, Asik G, Kesli R . A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea. Balkan Med J. 2016; 33(1):80-6. PMC: 4767316. DOI: 10.5152/balkanmedj.2015.15159. View

Guh A, Hatfield K, Winston L, Martin B, Johnston H, Brousseau G . Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates. Clin Infect Dis. 2019; 69(10):1667-1674. PMC: 6612464. DOI: 10.1093/cid/ciz009. View

10.

Khanafer N, Barbut F, Eckert C, Perraud M, Demont C, Luxemburger C . Factors predictive of severe Clostridium difficile infection depend on the definition used. Anaerobe. 2015; 37:43-8. DOI: 10.1016/j.anaerobe.2015.08.002. View

11.

Crobach M, Planche T, Eckert C, Barbut F, Terveer E, Dekkers O . European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016; 22 Suppl 4:S63-81. DOI: 10.1016/j.cmi.2016.03.010. View

12.

Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston D, Hernandez A . Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015; 36(4):452-60. DOI: 10.1017/ice.2014.88. View

13.

Williamson D, Basu I, Freeman J, Swager T, Roberts S . Improved detection of toxigenic Clostridium difficile using the Cepheid Xpert C difficile assay and impact on C difficile infection rates in a tertiary hospital: a double-edged sword. Am J Infect Control. 2012; 41(3):270-2. DOI: 10.1016/j.ajic.2012.03.025. View

14.

Kwon J, Olsen M, Dubberke E . The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am. 2015; 29(1):123-34. DOI: 10.1016/j.idc.2014.11.003. View

15.

Polage C, Gyorke C, Kennedy M, Leslie J, Chin D, Wang S . Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA Intern Med. 2015; 175(11):1792-801. PMC: 4948649. DOI: 10.1001/jamainternmed.2015.4114. View

16.

Longtin Y, Trottier S, Brochu G, Paquet-Bolduc B, Garenc C, Loungnarath V . Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 2012; 56(1):67-73. DOI: 10.1093/cid/cis840. View

17.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

18.

Kunishima H, Ohge H, Suzuki H, Nakamura A, Matsumoto K, Mikamo H . Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. J Infect Chemother. 2022; 28(8):1045-1083. DOI: 10.1016/j.jiac.2021.12.011. View

19.

Yamada Y, Miyazaki M, Kushima H, Komiya Y, Matsuo K, Uchiyama M . Association between disease severity according to "MN criteria" and 30-day mortality in patients with Clostridioides difficile infection. J Infect Chemother. 2022; 28(6):757-761. DOI: 10.1016/j.jiac.2022.02.014. View

20.

Johnson S, Louie T, Gerding D, Cornely O, Chasan-Taber S, Fitts D . Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014; 59(3):345-54. DOI: 10.1093/cid/ciu313. View